XML 31 R18.htm IDEA: XBRL DOCUMENT v3.5.0.2
Summary of Unaudited Quarterly Financial Information
 12 Months Ended
Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]  
Summary of Unaudited Quarterly Financial Information
Summary of Unaudited Quarterly Financial Information

As discussed in Correction of Previously Reported Financials in Note 1 of the previously filed Annual Report on Form 10-K on February 26, 2016, management opted to restate certain amounts in the previously reported financial statements as of and for the three and nine months ended September 30, 2015 to correct an immaterial error in the calculation of certain capital loss carry-forwards at September 30, 2015 related to the sale of the Avinza product line. The restated amounts are set forth in the following tables (in thousands, except share data):
 
Three months ended,
 
Nine months ended,
 
September 30, 2015
 
September 30, 2015
 
Previously Reported in 10-Q
 
Restated
 
Previously Reported in 10-Q
 
Restated
Income tax benefit
$
217,255

 
$
219,362

 
$
216,976

 
$
219,083

Net income
224,539

 
226,646

 
248,857

 
250,964

Basic net income per share
$
11.29

 
$
11.40

 
$
12.61

 
$
12.71

Diluted net income per share
$
10.46

 
$
10.56

 
$
11.78

 
$
11.88



 
As of September 30, 2015
 
Previously Reported in 10-Q
 
Restated
Long-term deferred tax assets
$
206,423

 
$
208,530

Accumulated deficit
(410,458
)
 
(408,351
)

In addition, As discussed in 2015 Restatement in Note 1 of this Annual Report on Form 10K/A, the Company corrected accounting errors related to its DTA at September 30, 2015 by restating the previously reported financial statements as of and for the three months and nine months ended September 30, 2015. The restated amounts are set forth in the following tables:











The effects of these prior period corrections on the condensed consolidated statement of operations and comprehensive income are as follows
 
Nine months ended September 30, 2015
 
As Previously Reported in 10-K(1)
 
Adjustments
 
As Restated
Income tax benefit
$
219,083

 
$
(27,481
)
 
$
191,602

Net income
250,964

 
(27,481
)
 
223,483

Comprehensive income
251,351

 
(27,481
)
 
223,870

Basic earnings per share
12.71

 
(1.38
)
 
11.33

Diluted earnings per share data
11.88

 
(1.30
)
 
10.58

     Basic
19,887

 
—

 
19,887

     Diluted
21,122

 
—

 
21,122

 
Three months ended September 30, 2015
 
As Previously Reported in 10-K(1)
 
Adjustments
 
As Restated
Income tax benefit (expense)
$
219,362

 
$
(27,481
)
 
$
191,881

Net income
226,646

 
(27,481
)
 
199,165

Comprehensive income
222,981

 
(27,481
)
 
195,500

Basic earnings per share
11.40

 
(1.39
)
 
10.01

Diluted earnings per share data
10.56

 
(1.28
)
 
9.28



The effects of these prior period corrections on the condensed consolidated balance sheet is as follows
 
As of September 30, 2015
 
As Previously Reported in 10-K(1)
 
Adjustments
 
As Restated
Deferred income taxes
$
208,530

 
$
(27,481
)
 
$
181,049

Total assets
523,807

 
(27,481
)
 
496,326

Accumulated deficit
(408,351
)
 
(27,481
)
 
(435,832
)
Total stockholders' equity
294,288

 
(27,481
)
 
266,807

Total liabilities and stockholders' equity
523,807

 
(27,481
)
 
496,326

(1) The Company opted to restate certain amounts in the previously reported financial statements as of and for the three and nine months ended September 30, 2015 to correct an immaterial error in the calculation of certain capital loss carry-forwards at September 30, 2015 related to the sale of the Avinza product line, which amounted to $2.1 million.


The corrections did not have any impact on the company's cash flow statements for any period.
The following is a summary of the unaudited quarterly results of operations for the years ended December 31, 2015 and 2014 (in thousands).
 
 
Quarter ended
 
March 31
 
June 30
 
September 30      Restated
 
December 31
2015
 
 
 
 
 
 
 
Total revenues
$
14,602

 
$
18,418

 
$
17,701

 
$
21,193

Total operating costs and expenses
11,253

 
14,053

 
9,104

 
10,175

Income tax (expense) benefit
(15
)
 
(265
)
 
191,881

 
514

Income from continuing operations
(89
)
 
22,027

 
199,165

 
6,341

Net loss attributable to noncontrolling interests
(843
)
 
(1,537
)
 
—

 
—

Net income
754

 
23,564

 
199,165

 
6,341

Basic per share amounts:
 
 
 
 
 
 
 
Net income
$
0.04

 
$
1.19

 
$
10.01

 
$
0.32

Diluted per share amounts:
 
 
 
 
 
 
 
Net income
$
0.04

 
$
1.11

 
$
9.28

 
$
0.29

 
 
 
 
 
 
 
 
Weighted average shares—basic
19,612

 
19,725

 
19,887

 
19,933

Weighted average shares—diluted
20,631

 
21,276

 
21,460

 
21,542

2014
 
 
 
 
 
 
 
Total revenues
$
15,958

 
$
10,608

 
$
14,973

 
$
22,999

Total operating costs and expenses
10,858

 
9,250

 
11,441

 
13,363

Income tax expense
(53
)
 
47

 
(124
)
 
(280
)
Income from continuing operations
2,097

 
1,288

 
777

 
6,730

Net loss attributable to noncontrolling interests
—

 
(304
)
 
(503
)
 
(325
)
Net income
2,097

 
1,592

 
1,280

 
7,055

Basic per share amounts:
 
 
 
 
 
 
 
     Net income
$
0.10

 
$
0.08

 
$
0.06

 
$
0.35

Diluted per share amounts:
 
 
 
 
 
 
 
     Net income
0.10

 
0.07

 
0.06

 
0.34

 
 
 
 
 
 
 
 
Weighted average shares—basic
20,601

 
20,738

 
20,417

 
19,878

Weighted average shares—diluted
21,208

 
21,780

 
21,345

 
20,792